Namely, each of the PPARs—PPARα, PPARβ/δ and PPARγ—is involved in maintaining metabolic homeostasis, which makes them eligible candidates for the treatment of MASLD. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.